WHO ICTRP trial
A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in…
ACTRN12615000407594 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12615000407594 |
|---|---|
| Public title | A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in patients with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT) Glioblastoma (brain cancer) (VERTU study) |
| Scientific title | A Randomised Phase II study of veliparib and radiotherapy with adjuvant temozolomide and veliparib versus standard radiotherapy and temozolomide followed by temozolomide in patients with newly diagnosed glioblastoma with unmethylated O (6)-methylguanine-DNA methyltransferase |
| Primary sponsor | The University of Sydney |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia |
| Conditions | Glioblastoma Multiforme; Glioblastoma Multiforme;Cancer - Brain |
| Interventions | Eligible participants will be randomised to the study in 2:1 ratio to either Experimental group or Standard group. The experimental group will receive veliparib capsules 200mg per oral two times per day for 6 weeks with concurrent… |
| Registration date | Apr 30, 2015 |
| Target size | 120 |
| Secondary IDs | Nil known |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: